- Home
- TCRX vs WLGS Comparison
TCRX vs WLGS Comparison
Compare TCRX & WLGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- WLGS
- Stock Information
- Founded
- TCRX 2018
- WLGS 1981
- Country
- TCRX United States
- WLGS Hong Kong
- Employees
- TCRX N/A
- WLGS N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- WLGS Engineering & Construction
- Sector
- TCRX Health Care
- WLGS Consumer Discretionary
- Exchange
- TCRX Nasdaq
- WLGS Nasdaq
- Market Cap
- TCRX 98.5M
- WLGS 98.9M
- IPO Year
- TCRX 2021
- WLGS 2023
- Fundamental
- Price
- TCRX $1.38
- WLGS $0.27
- Analyst Decision
- TCRX Strong Buy
- WLGS
- Analyst Count
- TCRX 6
- WLGS 0
- Target Price
- TCRX $9.83
- WLGS N/A
- AVG Volume (30 Days)
- TCRX 442.7K
- WLGS 4.5M
- Earning Date
- TCRX 03-05-2025
- WLGS 04-08-2025
- Dividend Yield
- TCRX N/A
- WLGS N/A
- EPS Growth
- TCRX N/A
- WLGS N/A
- EPS
- TCRX N/A
- WLGS 0.02
- Revenue
- TCRX $2,816,000.00
- WLGS $7,272,879.00
- Revenue This Year
- TCRX $32.21
- WLGS N/A
- Revenue Next Year
- TCRX $118.35
- WLGS N/A
- P/E Ratio
- TCRX N/A
- WLGS $14.79
- Revenue Growth
- TCRX N/A
- WLGS 66.93
- 52 Week Low
- TCRX $1.28
- WLGS $0.23
- 52 Week High
- TCRX $9.69
- WLGS $9.66
- Technical
- Relative Strength Index (RSI)
- TCRX 31.10
- WLGS 27.50
- Support Level
- TCRX $1.44
- WLGS $0.23
- Resistance Level
- TCRX $1.76
- WLGS $5.85
- Average True Range (ATR)
- TCRX 0.17
- WLGS 0.52
- MACD
- TCRX -0.01
- WLGS -0.41
- Stochastic Oscillator
- TCRX 16.39
- WLGS 0.69
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.